FDA ZAYNICH coverage for business development, investment, and market access teams
Wockhardt has achieved a historic milestone with the FDA approval of ZAYNICH, a novel antibiotic. This development signals potential growth opportunities in the pharmaceutical sector.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
